title: Docetaxel/ TS-1 with radiation for unresectable squamous cell carcinoma of the esophagus--a phase II trial.
abstract: BACKGROUND
  We tried a new regimen of docetaxel / TS-1 (tegafur-gimestat-otastat potassium) combined with radiation for squamous cell carcinoma of the esophagus in a phase II trial.
  
  
  METHODS
  The patients, whose tumor invaded other organs without other organ metastasis, were given TS-1 (60 mg/m2/day) from days 1 to 14, and docetaxel (20-30 mg/m2) on days 1 and 8. They received radiation in 2.0 Gy from days 1 to 21. Patients were given a seven-day rest after the first course, and then were treated with the same regimen from days 28 to 49.
  
  
  RESULTS
  Seventeen cases were enrolled in the study. The response rate was 76.4% (13/17). The overall 5-year survival rate was 29.6% (5/17) and median survival time was 15.2 months. Adverse events more than grade 3 occurred in 10 cases.
  
  
  CONCLUSIONS
  This combination therapy may be one of the most effective treatments because of its lower rate of non-hematological adverse events and higher response rate. Three cases also underwent salvage surgery when the tumor recurred, and in one case, chemoradiation to a metastatic nodule on the thoracic wall was added.
authors: Department of Digestive Surgery, Kawasaki Medical School, Kurashiki City, Okayama, Japan h-matsu@med.kawasaki-m.ac.jp.
authors: Hideo
authors: H
authors: Matsumoto
authors: Department of Digestive Surgery, Kawasaki Medical School, Kurashiki City, Okayama, Japan.
authors: Hisako
authors: H
authors: Kubota
authors: Department of Digestive Surgery, Kawasaki Medical School, Kurashiki City, Okayama, Japan.
authors: Masaharu
authors: M
authors: Higashida
authors: Department of Radiology, Kawasaki Medical School, Kurashiki City, Okayama, Japan.
authors: Eisaku
authors: E
authors: Yoden
authors: Department of Radiology, Kawasaki Medical School, Kurashiki City, Okayama, Japan.
authors: Junichi
authors: J
authors: Hiratsuka
authors: Department of Gastroenterological Medicine, Kawasaki Medical School, Kurashiki City, Okayama, Japan.
authors: Ken
authors: K
authors: Haruma
authors: Department of Digestive Surgery, Kawasaki Medical School, Kurashiki City, Okayama, Japan.
authors: Masafumi
authors: M
authors: Nakamura
authors: Department of Digestive Surgery, Kawasaki Medical School, Kurashiki City, Okayama, Japan.
authors: Toshihiro
authors: T
authors: Hirai
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D000077143:Docetaxel; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D043823:Taxoids / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage
chemical_list: D011725:Pyridines; D043823:Taxoids; D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid; C104201:gimeracil
keywords: Docetaxel; TS-1; chemoradiation; unresectable squamous cell carcinoma of esophagus